Druggability & Clinical Context
Druggability
Low
Score: 0.42
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
12
Known Drugs:
4
Approved:
0
In Clinical Trials:
0
Drug Pipeline (4 compounds)
3 Preclinical
Therapeutic Areas:Alzheimer's disease Neurodegeneration Frontotemporal dementia Amyotrophic lateral sclerosis (ALS) Parkinson's disease Neuroinflammation Microglial dysfunction disorders
Druggability Rationale: TREM2 demonstrates medium druggability (0.55) due to its well-characterized extracellular immunoglobulin domain amenable to antibody targeting, supported by 12 available PDB structures at high resolution (1.47 Ć
). The validated biological mechanism (loss-of-function mutations in AD) and advanced clinical candidates (AL002 in Phase II) confirm target tractability, though the medium score reflects challenges in achieving optimal microglial activation without immunological complications.
Mechanism: Agonist antibodies that enhance TREM2 signaling to promote microglial function
Drug Pipeline (4 compounds)
3 Preclinical
Known Drugs:AL002 (latozinemab) (Phase II) ā Anti-TREM2 agonist antibody for AD (Alector/AbbVie)
AL044 (preclinical) ā Anti-TREM2 antibody, enhanced microglial phagocytosis
DNL919 (preclinical) ā Brain-penetrant TREM2 agonist (Denali)
4D9 antibody (preclinical) ā TREM2 agonist antibody, enhances microglial function
Structural Data:PDB (12) āAlphaFold āCryo-EM ā
Binding Pocket Analysis:TREM2 lacks a traditional small-molecule binding pocket; the functional epitope resides on the extracellular immunoglobulin variable domain (IgV-set domain), making it optimally targeted by monoclonal antibodies or antibody fragments that stabilize active conformations. Structural data (PDB: 5ELI, 5UD7, 6XDS) reveal the ligand-binding interface and N-terminal region critical for receptor dimerization and signaling initiation.
Selectivity & Safety Considerations
TREM2 selectivity is relatively favorable as it is primarily expressed on myeloid cells (microglia, macrophages, dendritic cells) with restricted CNS distribution, minimizing off-target peripheral immune activation. However, antibody-based agonists must carefully avoid FcĪ³ receptor cross-linking that could trigger unintended immune responses or neurotoxic cytokine release.